[Skip to content]

Cancer Advice - from leading UK Cancer Specialists
Find information
In this section...
On this site...

High dose Interleukin-2 (hd Il-2) versus low dose Il-2 plus Interferon in metastatic renal/kidney cancer

Optimisation of immunotherapy for metastatic renal cancer is a 'work in progress' subject. At this year's American Society of Clinical Oncology meeting, data from Boston were presented suggesting a slighty improved response rate for high dose intravenous IL-2 over the more convenient to administer subcutaneous IL-2 and interferon regime.This work must yet be finalised and other immunotherapy methods are appearing, including the interesting New England Journal of Medicine paper from earlier this year describing responses to allogeneic stem cell infusions.